In a trial involving patients with metastatic melanoma, treatment with either a BRAF inhibitor (vemurafenib) or a BRAF/MEK inhibitor combination (dabrafenib and trametinib) experienced a significant increase in CD8+ T lymphocyte infiltration, as confirmed by tumor biopsy [34]. This evidence concerns the gene MAP2K7 and neoplasm.